Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App




Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

By LabMedica International staff writers
Posted on 09 Sep 2025

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. More...

Metastatic breast cancer is rising in younger populations and remains the leading cause of breast cancer-related death. Meanwhile, biliary tract cancer is often diagnosed at advanced stages and carries a poor prognosis with limited treatment options. HER2 is a receptor protein expressed in a variety of cancers and serves as a predictive biomarker to help determine if a patient will respond to HER2-targeted therapy. HER2 interpretation in breast cancer continues to evolve beyond the traditional "positive" or "negative" classifications. Now, a new companion diagnostic test can help expand patient access to personalized treatment for breast cancer and biliary tract cancer.

Roche’s (Basel, Switzerland) VENTANA HER2 (4B5) Rabbit Monoclonal Primary Antibody RxDx assay is intended to identify HR-positive metastatic breast cancer patients with HER2-ultralow status who may be eligible for treatment with ENHERTU. The test can also help identify patients with HER2-positive biliary tract cancer who have an immunohistochemistry score of 3+ and are eligible for treatment with ZIIHERA.

The VENTANA HER2 (4B5) test was used in the DESTINY-Breast06 clinical trial, which showed significant improvement in progression-free survival with ENHERTU compared to standard chemotherapy in patients with HER2-low and HER2-ultralow metastatic breast cancer.

The assay also demonstrated high concordance with HER2 FISH and achieved consistently high proficiency scores across laboratories, ensuring robust validation. The test standardizes immunohistochemistry processes and minimizes variability, ensuring accurate and reliable HER2 assessment.

Roche has received CE IVDR approval for the HER2 (4B5) companion diagnostic test to identify HER2-ultralow breast cancer and biliary tract cancer patients. This expands personalized treatment options for populations with limited therapies. By driving diagnostic certainty, the test empowers laboratories and clinicians to match patients with advanced therapies, ultimately improving care and outcomes across cancer types.

"This is about creating new options for patients facing some of the toughest cancers," said Jill German, Head of Pathology Lab at Roche Diagnostics. "Our understanding of HER2 is rapidly evolving, and this expanded approval ensures our diagnostics are leading the way. We're enabling clinicians to unlock personalized, life-altering treatments for patients who urgently need them."

Related Links:
Roche 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automatic CLIA Analyzer
Shine i6000
Gold Member
Automatic Hematology Analyzer
CF9600
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.